{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T15:02:25Z","timestamp":1720710145182},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.clml.2015.02.011","type":"journal-article","created":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T12:09:33Z","timestamp":1439899773000},"page":"S80-S84","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S","title":["Assessment of Molecular Markers in AML Patients: A Hospital-Based Study in Lebanon"],"prefix":"10.1016","volume":"15","author":[{"given":"Layal","family":"El Halabi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Djaffar-Jureidini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noha","family":"Hakime","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghada","family":"Saidy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabil","family":"Chamseddine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.02.011_bib1","doi-asserted-by":"crossref","first-page":"984","DOI":"10.6004\/jnccn.2012.0103","article-title":"Acute myeloid leukemia","volume":"10","author":"O'Donnell","year":"2012","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2015.02.011_bib2","series-title":"Cancer Facts and Figures\u00a02014","author":"American Cancer Society","year":"2014"},{"key":"10.1016\/j.clml.2015.02.011_bib3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.02.011_bib4","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"110","article-title":"Acute myeloid leukaemia with recurrent genetic abnormalities","author":"Arber","year":"2008"},{"key":"10.1016\/j.clml.2015.02.011_bib5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.011_bib6","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2012-03-419622","article-title":"A\u00a0novel hierarchical prognostic model of AML solely based on molecular mutations","volume":"120","author":"Grossmann","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.011_bib7","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","article-title":"Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia","volume":"13","author":"Van Dongen","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.02.011_bib8","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.011_bib9","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJM199811053391901","article-title":"Complete remission after treatment of\u00a0acute promyelocytic leukemia with arsenic trioxide","volume":"339","author":"Soignet","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.02.011_bib10","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1182\/blood.V87.1.308.308","article-title":"High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia","volume":"87","author":"Douer","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.011_bib11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/blood.V89.1.348","article-title":"Promyelocytic leukemia in Mexican Mestizos","volume":"89","author":"Ruiz-Arguelles","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.011_bib12","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1182\/blood.V88.1.377a.377a","article-title":"High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia","volume":"88","author":"Otero","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.011_bib13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/ajh.20032","article-title":"High incidence of acute promyelocytic leukemia in the Caucasian population: the Costa Rica experience","volume":"76","author":"Boza","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2015.02.011_bib14","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/oxfordjournals.annonc.a058400","article-title":"Childhood acute promyelocytic leukemia in Nicaragua","volume":"4","author":"Malta Corea","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2015.02.011_bib15","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0145-2126(00)00012-6","article-title":"High relative proportion of acute promyelocytic leukemia in children: experience of a multicenter study in Cuba","volume":"24","author":"Hernandez","year":"2000","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.02.011_bib16","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood.V88.6.2357.bloodjournal8862357","article-title":"About the increased frequency of acute promyelocytic leukemia among Latinos: the experience from a center in Spain","volume":"88","author":"Tomas","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.011_bib17","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood.V81.8.2209.2209","article-title":"Diagnosis and incidence of acute\u00a0promyelocytic leukemia (FAB M3 and M3 variant) in childhood","volume":"81","author":"Cantu-Rajnoldi","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.011_bib18","first-page":"188","article-title":"High frequency of acute promyelocytic leukemia in northwest Iran","volume":"5","author":"Ziaei","year":"2004","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.clml.2015.02.011_bib19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00008469-200608000-00011","article-title":"Incidence rates of acute promyelocytic leukemia among Hispanics, blacks, Asians, and non-Hispanic whites in the United States","volume":"15","author":"Matasar","year":"2006","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.clml.2015.02.011_bib20","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1126\/science.8511584","article-title":"Who are the Europeans?","volume":"260","author":"Piazza","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.clml.2015.02.011_bib21","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/sj.leu.2403099","article-title":"FLT3: IT does matter in leukemia","volume":"17","author":"Levis","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.02.011_bib22","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1182\/blood-2005-05-2174","article-title":"Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype","volume":"106","author":"Boissel","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.011_bib23","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2006-07-012252","article-title":"Acute myeloid leukemia carrying cytoplasmic\/mutated nucleophosmin (NPMc\u00a0+ AML): biological and clinical features","volume":"109","author":"Falini","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.011_bib24","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2005-06-2248","article-title":"Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype","volume":"106","author":"Schnittger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.011_bib25","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.011_bib26","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1182\/blood-2002-05-1440","article-title":"Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML study group Ulm","volume":"100","author":"Fr\u00f6hling","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.011_bib27","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","article-title":"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies","volume":"97","author":"Yamamoto","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.011_bib28","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1631\/jzus.B1000052","article-title":"FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics","volume":"11","author":"Wang","year":"2010","journal-title":"J\u00a0Zhejiang Univ Sci\u00a0B"},{"key":"10.1016\/j.clml.2015.02.011_bib29","first-page":"1429","article-title":"Frequency of NPM1 mutations in Pakistani acute myeloid leukemia patients","volume":"45","author":"Ali","year":"2013","journal-title":"Pakistan J Zool"},{"key":"10.1016\/j.clml.2015.02.011_bib30","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1155\/2013\/582569","article-title":"Mutations of NPM1 and FLT3 genes in acute myeloid leukemia and their association with clinical and immunophenotypic features","volume":"35","author":"Chauhan","year":"2013","journal-title":"Dis Markers"},{"key":"10.1016\/j.clml.2015.02.011_bib31","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1182\/blood-2008-09-179895","article-title":"Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome","volume":"113","author":"Wouters","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.011_bib32","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrc2943","article-title":"Acute promyelocytic leukaemia: novel insights into the mechanisms of cure","volume":"10","author":"De The","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2015.02.011_bib33","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood.V72.2.567.567","article-title":"Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia","volume":"72","author":"Huang","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.011_bib34","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1182\/blood-2006-04-015743","article-title":"Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors","volume":"108","author":"Levis","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.011_bib35","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.bbmt.2011.07.011","article-title":"Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib","volume":"17","author":"Sharma","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2015.02.011_bib36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood.V120.21.48.48","article-title":"Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients\u00a0\u226560 years of age with FLT3 ITD positive or negative relapsed\/refractory acute myeloid leukemia (abstract 48)","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.011_bib37","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/leu.2012.115","article-title":"Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia","volume":"26","author":"Stone","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.02.011_bib38","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2010-08-301796","article-title":"Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse","volume":"117","author":"Levis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.011_bib39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood.V120.21.141.141","article-title":"Crenolanib (CP-868,596) is a potent and selective type I FLT3 inhibitor that retains activity against AC220 resistance-causing FLT3 kinase domain mutants (abstract 141)","volume":"120","author":"Smith","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.011_bib40","doi-asserted-by":"crossref","first-page":"e97116","DOI":"10.1371\/journal.pone.0097116","article-title":"Targeting oncoprotein stability overcomes drug\u00a0resistance caused by FLT3 kinase domain mutations","volume":"9","author":"Yu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2015.02.011_bib41","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1038\/bcj.2011.43","article-title":"Pacritinib (SB1518), a JAK2\/FLT3 inhibitor for the treatment of acute myeloid leukemia","volume":"1","author":"Hart","year":"2011","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2015.02.011_bib42","doi-asserted-by":"crossref","unstructured":"Moore AS, Faisal A, Bavetsiaset V, et\u00a0al. Resistance to selective FLT3 inhibitors, driven by FLT3 ligand and FLT3 point mutations, can be overcome with the dual FLT3-aurora kinase inhibitor CCT241736 (abstract 3492), 1490-1490.","DOI":"10.1182\/blood.V118.21.3492.3492"},{"key":"10.1016\/j.clml.2015.02.011_bib43","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood.V122.21.3965.3965","article-title":"The combination of FLT3 inhibition and hypomethylation confers synergistic anti-leukemic effects on FLT3\/ITD positive AML cell lines and primary cells (abstract 3965)","volume":"122","author":"Konig","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.011_bib44","doi-asserted-by":"crossref","unstructured":"Fiskus WBR, Karissa P. Co-treatment with NPM1 antagonist and FLT3 inhibitor or pan-histone deacetylase inhibitor exerts superior efficacy against cultured and primary human AML cells co-expressing mutant NPM1 and FLT3-ITD; AACR 104th annual meeting; 2013; 2013.","DOI":"10.1158\/1538-7445.AM2013-2034"},{"key":"10.1016\/j.clml.2015.02.011_bib45","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/ejh.12334","article-title":"Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations","volume":"93","author":"Guenounou","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2015.02.011_bib46","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.humpath.2012.05.003","article-title":"IDH mutations in acute myeloid leukemia","volume":"43","author":"Rakheja","year":"2012","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clml.2015.02.011_bib47","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1126\/science.1234769","article-title":"Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation","volume":"340","author":"Wang","year":"2013","journal-title":"Science"},{"issue":"19 suppl","key":"10.1016\/j.clml.2015.02.011_bib48","article-title":"Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies (abstract CT103)","volume":"74","author":"Stein","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2015.02.011_bib49","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1200\/JCO.2013.50.2047","article-title":"Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group","volume":"32","author":"Janin","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.011_bib50","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1182\/blood-2010-09-309674","article-title":"Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1","volume":"118","author":"Balusu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.011_bib51","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","article-title":"Potent inhibition of DOT1L as treatment of MLL-fusion leukemia","volume":"122","author":"Daigle","year":"2013","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015000403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015000403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T04:57:40Z","timestamp":1599454660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015000403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":51,"alternative-id":["S2152265015000403"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.02.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of Molecular Markers in AML Patients: A Hospital-Based Study in Lebanon","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}